A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis

被引:0
作者
Leon A. Adams
Paul Angulo
Jan Petz
Jill Keach
Keith D. Lindor
机构
[1] University of Western Australia,School of Medicine and Pharmacology, Sir Charles Gairdner Hospital
[2] Mayo Clinic,Department of Gastroenterology and Hepatology
来源
Hepatology International | 2010年 / 4卷
关键词
Ursodeoxycholic acid; Nonalcoholic steatohepatitis; Aminotransaminase;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:628 / 633
页数:5
相关论文
共 135 条
[1]  
Browning JD(2004)Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 1387-1395
[2]  
Szczepaniak LS(2005)The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 113-121
[3]  
Dobbins R(2003)A randomized trial of a low-carbohydrate diet for obesity N Engl J Med 348 2082-2090
[4]  
Adams LA(2006)A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2297-2307
[5]  
Lymp JF(2007)Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180-1188
[6]  
St Sauver J(1998)Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production Mol Med 4 165-178
[7]  
Foster GD(1999)Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation Cell Death Differ 6 842-854
[8]  
Wyatt HR(1996)Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis Dig Dis Sci 41 1487-1493
[9]  
Hill JO(2004)Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 770-778
[10]  
Belfort R(2004)Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis Hepatology 40 693-698